You are here
Home 🌿 Medical Cannabis News 🌿 Cannabis Showing Promise For Treating Dermatitis In Dogs 🌿News Categories
Cannabis Showing Promise For Treating Dermatitis In Dogs

A cannabis-based formulation developed by Australia’s CannPal (ASX:CP1) has substantially reduced atopic dermatitis severity in dogs participating in clinical trial.
Atopic dermatitis is triggered by an allergic reaction after a dog ingests or inhales a substance they are sensitive to. As well as being an uncomfortable condition, repeated licking or scratching of an affected area can result in more serious issues, including infection.
According to CannPal, its DermaCann treatment substantially reduced Canine Atopic Dermatitis Extent and Severity Index (CADESI)-4 scoring by an average of 51% after 56 days of treatment. Importantly, the DermaCann treatment was well tolerated by all dogs, with no significant adverse events reported throughout the 8-week study.
30 dogs were expected to participate in the trial, but due to COVID-19 related restrictions only 13 dogs successfully completed treatment. While only a small number, CannPal says the differences between placebo and treatment indicate a “substantive and clinically relevant result.”
Of the 13 dogs, 8 dogs received DermaCann, while 5 were allocated the placebo. Dogs were dosed twice daily over the 56-day period and the placebo group saw a slight increase in CADESI-4 scoring.
“We’re extremely pleased to see such positive results from this study, which will support our authorisations for DermaCann® in various markets,” said CannPal Head of R&D, Dr Margaret Curtis.
The company will be seeking to register DermaCann as a nutraceutical for healthy skin and immune function for dogs in multiple markets, rather than as a medicine. As for when DermaCann might be available in Australia, the company notes it still needs to complete its Target Animal Safety study, which is a regulatory requirement for the registration of the product in Australia and New Zealand. CannPal anticipates a commencement date for this trial in the second half of this year.
Dermacann, which has been in development for three years, contains cannabidiol (CBD) extracted from hemp plants. Unlike the cannabinoid THC (tetrahydrocannabinol) that dogs are very sensitive to, CBD doesn’t appear to be problematic for our canine pals when used appropriately – but it should never be administered without first discussing with a vet.
CannPal has a goal of being global leader in the development of therapeutic products for companion animals, using plant compounds that act on the endocannabinoid system.
420 Intel is Your Source for Marijuana News
420 Intel is the leading source for cannabis news from around the world. Get the latest updates on cannabis legalization, politics and technology, as well as developments in medical and recreational marijuana news. Our commitment is to bring you the most important cannabis news stories every day of the week.
At 420 Intel we understand that effective marijuana industry news coverage is a constant endeavor. Every day stories develop regarding cannabis legalization, technological developments, and the medicinal benefits of marijuana use. Each new development carries the potential to impact the marijuana industry regionally, nationally, and internationally. 420 Intel is the marijuana industry news outlet that will keep you up to date on these developments and how they impact the world around you.
With the marijuana industry constantly evolving, you need a cannabis news outlet to keep you abreast of the pertinent information. At 420 Intel, we cover marijuana legalization news throughout the world, offer reliable information for cannabis business owners, detail technological advances that impact the marijuana industry, cover marijuana rallies from across the globe, and everything in between.
You can get 420 Intel news delivered directly to your inbox by signing up for our daily marijuana news, ensuring you’re always kept up to date on the ever-changing cannabis industry. To stay even better informed about marijuana legalization news follow us on Twitter, Facebook and LinkedIn.